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Abstract
Background: The kinin B1 receptor (B1R) is upregulated by pro-inflammatory cytokines and oxydative stress, which
are enhanced by transient receptor potential vanilloid subtype 1 (TRPV1) activation. To examine the link between
TRPV1 and B1R in inflammatory pain, this study aimed to determine the ability of TRPV1 to regulate microglial B1R
expression in the spinal cord dorsal horn, and the underlying mechanism.
Methods: B1R expression (mRNA, protein and binding sites) was measured in cervical, thoracic and lumbar spinal
cord in response to TRPV1 activation by systemic capsaicin (1-50 mg/kg, s.c) in rats pre-treated with TRPV1
antagonists (capsazepine or SB-366791), the antioxidant N-acetyl-L-cysteine (NAC), or vehicle. B1R function was
assessed using a tail-flick test after intrathecal (i.t.) injection of a selective B1R agonist (des-Arg
9-BK), and its
microglial localization was investigated by confocal microscopy with the selective fluorescent B1R agonist, [N
a-
bodipy]-des-Arg
9-BK. The effect of i.t. capsaicin (1 μg/site) was also investigated.
Results: Capsaicin (10 to 50 mg/kg, s.c.) enhanced time-dependently (0-24h) B1R mRNA levels in the lumbar
spinal cord; this effect was prevented by capsazepine (10 mg/kg, i.p.; 10 μg/site, i.t.) and SB-366791 (1 mg/kg, i.
p.; 30 μg/site, i.t.). Increases of B1R mRNA were correlated with IL-1b mRNA levels, and they were significantly
less in cervical and thoracic spinal cord. Intrathecal capsaicin (1 μg/site) also enhanced B1Rm R N Ai nl u m b a r
spinal cord. NAC (1 g/kg/d × 7 days) prevented B1R up-regulation, superoxide anion production and NF-kB
activation induced by capsaicin (15 mg/kg). Des-Arg
9-BK (9.6 nmol/site, i.t.) decreased by 25-30% the nociceptive
threshold at 1 min post-injection in capsaicin-treated rats (10-50 mg/kg) while it was without effect in control
rats. Des-Arg
9-BK-induced thermal hyperalgesia was blocked by capsazepine, SB-366791 and by antagonists/
inhibitors of B1R (SSR240612, 10 mg/kg, p.o.), glutamate NMDA receptor (DL-AP5, 10 μg/site, i.t.), substance P
NK-1 receptor (RP-67580, 10 μg/site, i.t.) and nitric oxide synthase (L-NNA, 10 μg/site, i.t.). The B1R fluorescent
agonist was co-localized with an immunomarker of microglia (Iba-1) in spinal cord dorsal horn of capsaicin-
treated rats.
Conclusion: This study highlights a new mechanism for B1R induction via TRPV1 activation and establishes a link
between these two pro-nociceptive receptors in inflammatory pain.
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Kinins are neuroactive peptides involved in pain and
inflammation [1-4]. They act through the activation of
two G-protein-coupled receptors (GPCR) denoted as B1
(B1R) and B2 (B2R) [5,6]. The B2R, activated by bradyki-
nin (BK) and Lys-BK, is widely and constitutively
expressed in central and peripheral tissues. The BK
metabolites, des-Arg
9-BK and Lys-des-Arg
10-BK, are the
preferential agonists of B1R. Whereas the B1R is virtually
absent in healthy conditions, it is upregulated after
exposure to pro-inflammatory cytokines, bacterial endo-
toxins and hyperglycaemia-induced oxidative stress
[7-10]. The induction of B1R involves the transcriptional
nuclear factor NF-B and MAP-kinase/P38 pathways
[6,11]. We have reported that spinal injection of B1R
agonist causes transient thermal hyperalgesia in type 1
diabetic rats due to release of sensory pro-inflammatory
mediators, notably substance P (SP), prostaglandins and
nitric oxide [1]. Furthermore, B1R antagonists reverse
thermal hyperalgesia and allodynia in various models of
type 1 and type 2 diabetes [4,12-15].
The transient receptor potential vanilloid subtype 1
(TRPV1) is known as a non-selective cationic channel
expressed in primary sensory C-fibers [16] and microglia
[17]. Its activation increases both calcium and sodium
influx [16]. TRPV1 knockout mice do not display ther-
mal hyperalgesia[18-20]. TRPV1 can be sensitized
through the phosphorylation of its C-terminal end by
protein kinases A and/or C [21,22]. It is activated by a
variety of stimuli such as heat > 43°C [16], acidification
[23], BK [24], nerve growth factor [24] and oxidative
stress [25]. It was recently shown that TRPV1 activation
by capsaicin increases reactive oxygen species (ROS)
production in mouse dorsal root ganglion (DRG) neu-
rons [26]. TRPV1-induced ROS production is thought
to involve increased cytosolic calcium influx and activa-
tion of NADPH oxidase [27]. Moreover, it has been sug-
gested that selective TRPV1 inhibition reduces the pro-
oxidant capacity of microglial NADPH oxidase [28].
This study was undertaken to determine whether
TRPV1 activation by capsaicin could enhance expression
of the pro-nociceptive B1R since both receptors are
involved in thermal hyperalgesia. Moreover, microglial
TRPV1 activation enhances pro-inflammatory cytokines
and oxidative stress, both known to trigger B1Ri n d u c -
tion through the NF-B pathway. Thus, microglia can
be considered to be a strategic target for B1R expression
as evidenced in a diabetic model of pain neuropathy
[29,30]. Our main objectives were to determine: 1- the
role of oxidative stress and pro-inflammatory cytokines
in capsaicin-induced B1R upregulation; 2- whether
newly induced B1R is functional and could induce ther-
mal hyperalgesia through release of spinal cord
mediators; and 3- the presence of B1R on microglia in
the spinal dorsal horn of capsaicin-treated rats by confo-
cal microscopy.
Methods
Experimental animals and care
All research procedures and the care of the animals
were in compliance with the guidelines of the Commit-
tee for Research and Ethical Issues of IASP and were
approved by the Animal Care Committees of Université
de Montréal and Pontificia Universidade Católica do Rio
Grande do Sul. Male Sprague-Dawley rats (200-225 g;
Charles River, St-Constant, Qc, Canada and CEMIB,
UNICAMP, Brasil) were housed two per cage, under
controlled conditions of temperature (23°C) and humid-
ity (50%), on a 12 h light-dark cycle (until surgery) and
allowed free access to normal chow diet (Charles River
Rodent) and tap water.
Intrathecal implantation of catheter and capsaicin
treatment
Four days after arrival, rats were anaesthetized with iso-
flurane and chronically implanted with an indwelling
intrathecal (i.t.) polyethylene catheter (PE-10; Intrame-
dic, Clay Adams, NJ, USA) at the vertebral lumbar level
(L3 to L6) through an incision made in the dura at the
atlanto-occipital junction [31]. The canula was secured
to the skull through two small parallel segments of PE-
60 glued with cyano-acrylate. Rats with apparent abnor-
mal behaviour or motor deficits were euthanized with
CO2 inhalation. Rats were housed permanently in the
testing laboratory under continuous light to prevent the
release of endogenous opioids which could alter noci-
ceptive threshold [32]. One week after surgery, six
groups of 7-8 rats received a single dose of capsaicin (1,
5, 10, 15, 25 and 50 mg/kg), injected subcutaneously at
the lumbar back skin level under mild anaesthesia with
pentobarbital (45 mg/kg, i.p.). The highest dose of 50
mg/kg was injected in two doses of 25 mg/kg at 12 h
intervals. Rats were used 24 h after capsaicin injection,
except for rats used for time-course experiments (trea-
ted for: 0, 8, 24 or 48 h). To evaluate directly the capa-
city of spinally expressed TRPV1 to induce B1R
expression, one group of rats received 1 μg of capsaicin
intrathecally at the lumbar region of the spinal cord.
Control rats received vehicle only (10% ethanol, 10%
Tween-80 and 80% saline 0.9%). Responses to des-Arg
9-
BK were measured using a tail-flick test prior to and 24
h after capsaicin injection.
Tail-flick test protocol
Experiments were always started in the morning at
around 10:00 H AM. Awake rats were placed in a plastic
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the reaction-time to remove the tail from a source of
noxious heat stimulus using either a tungsten lamp or a
hot water bath (50 ± 1°C) [33]. The average tail-flick
reaction times of control rats were 9.4 ± 0.2 s and 5.8 ±
0.3 s, when assessed with the tungsten lamp and the hot
water bath as heat stimuli, respectively. A 25 s cut-off
time was used to prevent tissue damage [31]. All rats
were tested for a maximum of four consecutive days.
During the first two days, rats received 10 μl of artificial
cerebrospinal fluid (aCSF) as training experiments and
to ensure that the intrathecal catheter was patent. On
the subsequent days, each testing trial lasted 45 min and
consisted of 9 measurements of tail-flick latency, spaced
by 5 min intervals. The initial three measurements were
used to determine baseline latency [31]. One minute
prior to the 4
th reading (t = 15 min), the vehicle (aCSF)
or an inhibitor was i.t. injected. Twelve min later, the
tested agonist (des-Arg
9-BK) or substance P (SP) (as
positive control) was administered through the same
route (t = 26 min), and its effect on the tail-flick latency
was measured 1 min later (t = 27 min). Three subse-
quent readings were made to assess the effect of the
agonist on the nociceptive threshold. The study design
for time and agonist doses (des-Arg
9-BK, 9.6 nmol; SP,
6.6 nmol) was based on previous studies showing that
SP and des-Arg
9-BK evoke a transient 5-10 min thermal
hyperalgesia that peaks 1 min post-injection [1,31,34].
Drugs and tested agonists were intrathecally injected
using a 50 μl Hamilton syringe with a total volume of
10 μl. The catheter, with a void volume of 10 μl, was
immediately flushed after drug injection by the adminis-
tration of 15 μl aCSF.
Pharmacological treatments
The hyperalgesic response induced by SP and des-Arg
9-
BK in the tail-flick test was characterized by determin-
ing the effects of the following selective antagonists/
inhibitors (10 μg/site) administered intrathecally 15 min
prior to the agonist: nitric oxide synthase (NOS): L-N
G-
Nitroarginine (L-NNA) [35], neurokinin-1 (NK-1) recep-
tor: [Imiro-1 (methoxy-2 phenyl)-2ethyl]-2 diphenyl-7.7
perhydroisoindolone-4-(3aR, 7aR) (RP-67580) [36], and
N-methyl-D-aspartic acid (NMDA) receptor: D, L-2-
amino-5- phosphonovaleric acid (DL-AP5) [37].
SSR240612 was used in this study as a selective and
orally active B1R antagonist. Dosage of SSR240612 (10
mg/kg, 3 h pre-treatment) was based on previous studies
showing that: i) des-Arg
9-BK-induced paw oedema in
mice is inhibited by 1 h pre-treatment with 3 and 10
mg/kg, p.o. of SSR240612 [38], and ii) allodynia and
high systolic blood pressure induced by insulin resis-
tance are prevented by a 3 h pre-treatment with
SSR240612 (IC50 of 5.5-7.1 mg/kg) [4,39]. Finally, we
used two generations of TRPV1 antagonists (capsaze-
pine and SB-366791) [16] to unequivocally demonstrate
that capsaicin effects are attributable to TRPV1 stimula-
tion. Capsazepine was administered intraperitoneally 1 h
before capsaicin challenge at a dose of 10 mg/kg [40] or
intrathecally at a dose of 10 μg/site [41]. SB-366791 [N-
(3-methoxyphenyl)-4-chlorocinnamide] is known as a
more selective and more potent TRPV1 antagonist than
capsazepine [42]. SB-366791 was administered intraperi-
toneally 1 h before capsaicin challenge at a dose of 1
mg/kg [43] or intrathecally at a dose of 30 μg/site [44].
Antioxidant treatment
Rats without intrathecal catheter received every day for
a period of 1-week the potent antioxidant N-acetyl-L-
cysteine (NAC) (1 g/kg/d) or the vehicle (sterile water)
by gavage [8]. On the 6
th day of treatment with NAC,
rats received a single injection of capsaicin (15 mg/kg, s.
c.) or its vehicle. Rats were sacrificed 24 h later under
inhalation with CO2.
Tissue preparation for autoradiography and microscopy
Twenty-four hours after capsaicin treatment, rats were
anaesthetised with CO2 inhalation and then decapitated.
Lower-lumbar (L3-L6) spinal cord was removed and fro-
zen in 2-methylbutane (cooled at -55 ± 5°C with liquid
nitrogen) and stored at -80°C. Spinal cords were
mounted in a gelatin block and serially cut into 20-μm
thick coronal sections with a cryostat. The sections were
thaw-mounted on 0.2% gelatin-0.033% chromium potas-
sium sulfate-coated slides and kept at -80°C for 1
month to allow sections adhesion to the coverslip
glasses.
Quantitative autoradiography
The density of kinin B1R binding sites was measured
with the radioligand [
125I]-HPP-desArg
10-Hoe140 (3-(4
hydroxyphenyl) propionyl-desArg
9-D-Arg
0[Hyp
3,T h i
5,
D-Tic
7,O i c
8]bradykinin) used at a concentration of 200
pM (specific activity: 2000 cpm/fmol) as described pre-
viously [3,8,15,29]. Non-specific binding was determined
for each capsaicin doses in the presence (1 μM) of the
selective B1R antagonist R-715 (AcLys[D-bNal
7, Ile
8]des-
Arg
9-BK) [45]. Scientific Imaging Films BIOMAX ™
MR
® (Amersham Pharmacia Biotech Canada) were jux-
taposed onto the slides in the presence of [
125I]-micro-
scales and exposed at room temperature for 7 days.
Autoradiograms were quantified by densitometry using
an MCID™ image analysis system (Imaging Research,
S t .C a t h a r i n e s ,O N ,C a n a d a ) .B r i e f l y ,t w e n t ym e a s u r e -
ments were made throughout the spinal cord dorsal
horn in 3 to 8 rats per group. A standard curve from
[
125I]-microscales was used to convert density levels into
fentomoles per milligram of protein [46]. Specific
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specific binding from that of total binding.
Confocal microscopy
The exhaustive protocol and specificity of the fluores-
cent B1R agonist have been described elsewhere [29].
Sections were dissected out under a binocular micro-
scope to specifically isolate the spinal cord dorsal horn.
Briefly, unfixed 20-μm sections were exposed for 90 min
to 50 μM[ N
a-bodipy]-des-Arg
9-BK (N
a-4,4,-difluoro-
5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionic
acid succinimidyl ester-des(Arg
9)-bradykinin) to label
the B1R. Slices were then incubated with a blocking buf-
fer (25 mM PIPES buffer supplemented with 3% bovine
serum albumin (BSA) and 3% donkey serum) to prevent
non-specific labeling. Antibody was diluted in blocking
buffer. Rabbit anti-ionized calcium binding adapter
molecule 1 (anti-Iba-1, Wako, Richmond, VA, Cat No:
#019-19741) at a concentration of 2 μg/ml was used to
label microglia [30]. The secondary antibody was rhoda-
mine anti-rabbit 1:500 (Chemicon, Hornby, ON, Cat
No: # R-6394).
Measurement of superoxide anion
In situ levels of O2 in the spinal cord were evaluated
with the oxidative fluorescent dye dihydroethidium
(DHE) as described earlier [47]. Cells are permeable to
DHE which specifically react with O2 to produce ethi-
dium bromide (EtBr) which is trapped by intercalation
with DNA. EtBr is excited at 518 nm with an emission
spectrum of 605 nm. Twenty-four hours post-capsaicin,
rats were anaesthetized with CO2 inhalation and then
decapitated. The lumbar spinal cord (L3-L6) was iso-
lated and serially cut into 20-μm thick sections and
placed on glass slides. On the day of experiment, slides
were exposed for 30 min in a light-protected humidified
chamber at 37°C to DHE (2 μM) for superoxide anion
labeling and to TO-PRO-3 1:5000 (Molecular Probes,
Eugene, OR, USA) for DNA staining. Sections were then
washed 3 times in sterile phosphate buffered saline
(PBS, pH7.4), coverslipped and observed using a confo-
cal microscope (Leica Microsystem Co., Germany).
Slides from the four groups (control, control + NAC,
capsaicin-treated, capsaicin-treated + NAC) were pro-
cessed and imaged in parallel. Laser settings were identi-
cal for acquisition of images from all sections. Computer
based analysis was performed with Image J software and
calculated using the following equation: I=∑ I/(A/N),
where I is the fluorescence intensity, ∑ I is the summa-
tion of all nuclei intensity, A is the total area of the
nuclei, and N is the number of nuclei used [47]. Data
are expressed as an average of total nuclei fluorescence
quantified on at least 4 nuclei/section on 4 sections/rat
from 4 different rats. Positive pixels regarding the co-
localisation of B1R and Iba-1 were determined following
the subtraction of mean pixel background level intensity
from total pixels.
SYBR green-based quantitative real-time PCR
Twenty-four hours after capsaicin injection, rats were
anaesthetized with CO2 inhalation and then decapitated.
Cervical (C2-C4), thoracic (T3-T5) and lumbar spinal
cord (L3-L6) segments were isolated and approximately
1 0m go ft i s s u ew e r ep u ti nR N A later stabilization
reagent (QIAGEN, Valencia, CA, USA). The protocol
for mRNA extraction, cDNA generation, SYBR green-
based quantitative RT-PCR and quantification has been
described elsewhere [29]. The PCR conditions were as
follows: 95°C for 15 min, followed by 46 cycles at 94°C
for 15 s, 60°C for 30 s and 72°C for 30 s. Real-time PCR
primer pairs were designed using Vector NTI and are
presented in Table 1.
Western blot
The extensive procedure has been described elsewhere
[48]. Briefly, 24 h after capsaicin treatment, rats were
anaesthetized with CO2 inhalation and then decapitated.
T h el u m b a rs p i n a lc o r d( L 3 - L 6 )w a si s o l a t e da n d
approximately 50 mg of tissue were put in PBS contain-
ing a cocktail of proteases inhibitors (Sigma-Aldrich,
Canada). Antibodies against B1R, p65NF-kB and dynein
(internal control) are presented in Table 2.
Drugs and solutions
Des-Arg
9-BK and SP were purchased from Bachem
Bioscience Inc. (King of Prussia, PA, USA). RP-67580
and SB-366791 were purchased from Tocris Cookson
Inc (Ellisville, MO, USA). The B1Ra n t a g o n i s t ,
SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-
[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)
amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]
phenyl)-N-isopropyl-N-methylpropanamide,fumarate],
w a sk i n d l yp r o v i d e db yS a n o f i - A v e n t i s( M o n t p e l l i e r ,
France). HPP-des-Arg
10- H o e 1 4 0w a ss y n t h e s i z e da tt h e
Research Institute of Biotechnology, National Research
Council of Canada (Montreal, Qc, Canada). R-715 was
kindly provided by Dr Fernand Gobeil (Pharmacology,
University of Sherbrooke, Sherbrooke, Qc, Canada).
[N
a-bodipy]-des-Arg
9-BK was synthesized by Dr. Pierr-
ette Gaudreau (Research Center CHUM, Université de
Montréal, Montréal, Qc, Canada) [29]. Dihydroethidium
was obtained from Molecular Probes (Invitrogen Cor-
poration, Carisbad, CA, USA) and suspended in DMSO
at a concentration of 10
-3 M ,a n ds t o r e da t- 2 0 ° Cu n t i l
use. Capsaicin, capsazepine, NAC, DL-AP5 and L-NNA
were purchased from Sigma-Aldrich Canada, Ltd (Oak-
ville, ON, Canada). For i.t. injections, SP, des-Arg
9-BK,
DL-AP5, L-NNA, RP-67580, SB-366791 and capsazepine
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pine were dissolved in sterile saline for i.p. injections.
SSR240612 was dissolved in dimethyl sulfoxide (DMSO,
0.5% v/v), ethanol (5% v/v) and Tween-80 (5% v/v). The
solution was completed in distilled water. The drug was
administered orally by gavage in a volume of 1 ml per
100 g of body weight [39]. Capsaicin was solubilized in
a mixture of 10% ethanol, 10% Tween-80 and 80% saline
0.9%.
Statistical analysis
Data were expressed as means ± S.E.M. of values
obtained from n rats. Only one treatment was given to a
rat. For the tail-flick test, data were calculated as a per-
centage of the maximum possible effect (% MPE)
according to the following formula: % MPE = 100 ×
(drug latency minus baseline latency/cut-off time minus
baseline latency) [1]. Statistical significance was deter-
mined with Student’s t-test for paired samples or with
one-way analysis of variance (ANOVA) followed by the
Bonferroni post-test for multiple comparisons. Data for
DHE labelling intensity were analysed with the non-
parametric Kruskal-Wallis post-test. Probability (P)
values less than 0.05 were considered to be statistically
significant.
Results
Increased B1R expression by capsaicin-induced TRPV1
activation
A 24-h-capsaicin treatment (10-50 mg/kg, s.c.) increased
significantly B1R mRNA levels in rat lumbar spinal cord
when compared with vehicle-treated rats. A dose of 15
mg/kg caused the highest increase of gene expression
(500-fold) at 24 h and the effect was almost gone at 48
h (Figure 1). In comparison, a dose of 50- mg/kg capsai-
cin caused a smaller enhancing effect on B1Rm R N A ,
which peaked at 8 h and declined thereafter (Figure 1B).
The increasing effect of 15 mg/kg capsaicin on B1R
mRNA was significantly less at the thoracic (T4) and
cervical (C2) spinal cord levels (Figure 2). Intrathecal
capsaicin (1 μg/site) reproduced to some extent the
effects of systemic capsaicin, as it significantly increased
B1R mRNA in the lumbar spinal cord in comparison
with vehicle-treated rats 24 h post-treatment (Figure 3).
Capsaicin-induced B1R up-regulation is likely asso-
ciated with TRPV1 activation as the increased B1R
mRNA expression evoked by 15 mg/kg capsaicin was
prevented by capsazepine (10 mg/kg, i.p. or 10 μg/site, i.
t.) and SB-366791 (1 mg/kg, i.p. or 30 μg/site, i.t.), when
injected 1 h beforehand (Figure 4).
Contrarily to B1R mRNA levels, the density of B1R
binding sites was dose-dependently increased at 15 and
50 mg/kg capsaicin (Figure 5). As depicted on autora-
diograms, B1R binding sites were displayed throughout
the grey matter of spinal cord in capsaicin-treated rats
and poorly in white matter. Such a distribution is in
accordance with B1R expression on spinal cord project-
ing C-fibres, astrocytes and microglia [29].
Effect of des-Arg
9-BK on tail-flick latency in capsaicin-
treated rats
The functionality of the B1R which is up-regulated by cap-
saicin in the spinal cord was assessed on thermal nocicep-
tion. Intrathecal injection of des-Arg
9-BK (9.6 nmol/site)
Table 1 Real-time PCR primer pairs.
Sequences Position Gen Bank
18 S forward 5’ TCA ACT TTC GAT GGT AGT CGC CGT 3’ 363 - 386 X01117
18 S reverse 5’ TCC TTG GAT GTG GTA GCC GTT TCT 3’ 470 - 447
B1 receptor forward 5’ GCA GCG CTT AAC CAT AGC GGA AAT 3’ 367 - 391 NM_030851
B1 receptor reverse 5’ CCA GTT GAA ACG GTT CCC GAT GTT 3’ 478 - 454
IL-1b forward 5’ TGT CAC TCA TTG TGG CTG TGG AGA 3’ 247 - 270 NM_031512
IL-1b reverse 5’ TGG GAA CAT CAC ACA CTA GCA GGT 3’ 411 - 388
TNF-a forward 5’ ATG ATC CGA GAT GTG GAA CTG GCA 3’ 160 - 183 NM_012675
TNF-a reverse 5’ AAT GAG AAG AGG CTG AGG CAC AGA 3’ 257 - 234
Table 2 Western Blot primary and secondary antibodies.
Primary antibodies Molecular weight Dilution Source
rabbit polyclonal anti-rat B1R 37 kDa 1:1000 Réjean Couture’s Laboratory [48]
rabbit polyclonal anti-rat p65NF-B 65 kDa 1:1000 SantaCruz Biotechnology (Cat number Sc-8008)
mouse monoclonal anti-rat dynein 70 kDa 1:20000 SantaCruz Biotechnology (Cat umber Sc-13524)
Secondary antibodies Protein detected Dilution Source
HRP-linked goat anti-rabbit B1R, p65NF-B 1:5000 SantaCruz Biotechnology (Cat number Sc-2077)
HRP-linked goat anti-mouse dynein 1:5000 SantaCruz Biotechnology (Cat number Sc-2005)
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rats or in rats treated with capsaicin at doses of 1 and 5
mg/kg, 24 h earlier (Figure 6A). However, the B1R agonist
dose-dependently decreased the tail-flick latency in rats
treated with doses from 10 to 50 mg/kg capsaicin. The
hyperalgesic response to the B1R agonist peaked l min
post-injection (-30%) and lasted about 5-10 min in rats
pre-treated with 15 mg/kg capsaicin (Figure 7). The
Figure 1 (A) Changes of B1R mRNA levels in the lumbar spinal cord of capsaicin-treated rats (0-50 mg/kg, s.c.).D a t ar e p r e s e n tt h e
means ± S.E.M. of 4 to 7 rats per group (a single dose of capsaicin per group, 24 h earlier). Comparison with the 0 mg/kg group is indicated by
* P < 0.05; ** P < 0.01. (B) Time-course effect (0 - 48 h) of 15 mg/kg (￿) and 50 mg/kg (□) capsaicin on lumbar spinal cord B1R mRNA expression
levels. Data represent the means ± S.E.M. of 4 rats per group. Comparison with the 0 h group (*) is indicated by ** P < 0.01; *** P < 0.001.
Shown are the responses in rats housed under constant light (A) or a 12 h-12 h light-dark cycle (B).
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9-BK was similar in inten-
sity, onset and duration than that evoked by substance P
(6.6 nmol/site, i.t.) [1,31,34]. Des-Arg
9-BK-induced ther-
mal hyperalgesia in capsaicin-treated rats was completely
prevented by the selective B1R antagonist SSR240612 (10
mg/kg, p.o.) (Figure 6B) and by both TRPV1-selective
antagonists: capsazepine (10 mg/kg, i.p. or 10 μg/site, i.t.)
and SB-366791 (1 mg/kg, i.p. or 30 μg/site, i.t.) when
Figure 2 Effect of 24 h capsaicin (15 mg/kg, s.c.) or its vehicle on B1Rm R N Ae x p r e s s i o nl e v e l si nc e r v i c a l( C 2 ) ,t h o r a c i c( T 4 )a n d
lumbar (L5) segments of rat spinal cord. Data represent the means ± S.E.M. of 4 rats per group. Comparison with vehicle (*) or lumbar
segment (+) is indicated by +,* P < 0.05; ** P < 0.01.
Figure 3 Effect of intrathecally injected capsaicin (1 μg/site, 24 h) or its vehicle on B1R mRNA expression level in lumbar spinal cord.
Data represent the means ± S.E.M. of 4 rats per group. Comparison with vehicle (*) is indicated by * P < 0.05.
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Page 7 of 17injected 1 h prior to capsaicin (Figure 6C). In contrast,
similar treatments with TRPV1 antagonists did not affect
t h eh y p e r a l g e s i cr e s p o n s ei n d u c e db ys u b s t a n c eP( 6 . 6
nmol/site, i.t.), showing the specificity of the inhibition
(Figure 6C). The TRPV1 antagonists (capsazepine (10 mg/
kg, i.p. or 10 μg/site, i.t.) and SB-366791 (1 mg/kg, i.p. or
30 μg/site, i.t.)) had no direct effect on baseline tail-flick
reaction time in control rats (Figure 8).
Figure 4 Effect of 1 h pre-treatment with TRPV1 antagonists (capsazepine (10 mg/kg, i.p. or 10 μg/site, i.t.) and SB-366791(1 mg/kg, i.p. or
30 μg/site, i.t.)) or vehicle (filled dotted bars) on the increased lumbar spinal cord B1R mRNA level induced by capsaicin (15 mg/kg, s.c.).
Data represent the means ± S.E.M. of 4 rats per group. Comparison with capsaicin pre-treated with the vehicle is indicated by + P < 0.01.
Figure 5 Autoradiograms (A) and quantitative densitometric analysis (B) of specific B1R binding sites in the grey matter of lumbar
spinal cord of rats treated with capsaicin (15 and 50 mg/kg, s.c.) or vehicle, 24 h earlier. Data represent the means ± S.E.M. of n rats
per group. Comparison with vehicle (*) is indicated by ** P < 0.01.
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Most of the current data were obtained in rats housed
under constant light with the intent to prevent the
release of endogenous opioid peptides [32] which could
interfere with the hyperalgesic response to substance P
in the rat tail-flick test [31,34]. To confirm that the
interruption of the circadian cycle by constant light did
not corrupt our findings, we run a series of experiments
Figure 6 (A) Effect of des-Arg
9-BK-induced thermal hyperalgesia in rats treated with capsaicin (1-50 mg/kg, s.c.) or vehicle, 24 h
earlier. (B) Effect of the selective B1R antagonist (SSR240612, 10 mg/kg, p.o.) administered 3 h prior to des-Arg
9-BK in capsaicin-treated rats (50
mg/kg, s.c.). (C) Effect of two TRPV1 antagonists (capsazepine 10 mg/kg, i.p. or 10 μg/site, i.t. and SB-366791 1 mg/kg, i.p. or 30 μg/site, i.t.) given
1h prior to capsaicin on thermal hyperalgesia induced by des-Arg
9-BK and SP in capsaicin-treated rats (15 mg/kg, s.c.). Shown are the maximal
hyperalgesic responses measured at 1 min post-injection of the agonist. Data represent the means ± S.E.M. of 5-7 rats per group. Comparison
with the vehicle (*) is indicated by: * P < 0.05; ** P < 0.01; ***P < 0.001.
Figure 7 Time-course effect of des-Arg
9-BK (9.6 nmol/site, i.t.) on thermal hyperalgesia in the tail-flick test from rats treated 24 h
earlier with capsaicin (15 mg/kg, s.c.). Shown are the responses in rats housed under constant light (A) or a 12 h-12 h light-dark cycle (B).
Data represent the means ± S.E.M. of 4 rats per group. Comparison with the 0 min group (*) is indicated by ** P < 0.01. No statistical
significance was seen between the two groups.
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that the time-course pattern of B1R agonist-induced
thermal hyperalgesia in 15 mg/kg capsaicin-treated rats
is similar in rats housed under constant light or under a
standard 12 h-12 h light-dark cycle (Figure 7). More-
over, increased B1R mRNA levels in the lumbar spinal
cord of rats treated with capsaicin (15 and 50 mg/kg, 24
h) under continuous light (Figure 1A) were not signifi-
cantly different from those measured in rats under the
12 h-12 h light dark-cycle (Figure 1B). Thus, these data
confirm that constant light exposure does not interfere
with our findings.
Mechanism underlying des-Arg
9-BK-induced hyperalgesia
Whereas control rats treated with SP (6.6 nmol/site, i.t.)
showed a significant decrease in tail-flick latency (-34%)
when compared with aCSF (-2%), des-Arg
9-BK (9.6
nmol/site, i.t.) had no effect (0%) (Figure 9). Significant
decreases in tail-flick latency were, however, achieved
with both des-Arg
9-BK (-29%) and SP (-41%) in rats
treated 24 h earlier with capsaicin (15 mg/kg, s.c.) in
comparison with aCSF. A 15-min pre-treatment with
either L-NNA (NOS inhibitor; 10 μg/site, i.t.), RP-67580
(NK-1R antagonist; 10 μg/site, i.t.) or DL-AP5 (NMDA-
Ra n t a g o n i s t ;1 0μg/site, i.t.) inhibited significantly the
response to both des-Arg
9-BK and SP. Whereas these
inhibitors had no direct effect in control rats (data not
shown), they caused antinociceptive effects in capsaicin-
treated rats (+51% for L-NNA; +29% for RP-67580 and
+9% for DL-AP5). Note that MPE was calculated from
baseline values obtained after inhibitor/antagonists
administration.
Microglial localisation of B1R in the spinal dorsal horn of
capsaicin-treated rats
As shown in Figure 10, immunofluorescence to the spe-
cific marker of microglia Iba-1 (red, A) and fluorescent
labeling with the specific B1Ra g o n i s t[ N
a-bodipy]-des-
Arg
9-BK (green, B) were co-localized (yellow, C) in
spinal cord dorsal horn of capsaicin-treated rats (15 mg/
kg, s.c., 24 h earlier). Note that 87 ± 4% of B1R-positive
pixels co-localized with Iba-1-positive pixels, suggesting
that B1R induced by capsaicin is mostly expressed by
lumbar spinal cord microglia.
Increased superoxide anion production and NF-B
activation in the spinal cord of capsaicin-treated rats
This series of experiments aimed to determine the con-
tribution of oxidative stress to the induction of B1Rf o l -
lowing TRPV1 activation. DHE staining (red staining,
Figure 11C) was significantly increased in nuclei
(labelled with TO-PRO-3 in blue) in the spinal dorsal
horn of rats treated with capsaicin (15 mg/kg, s.c., 24 h
earlier) when compared with control spinal cord (Figure
11A). This increase was abolished by a 1-week pre-treat-
ment with NAC (1 g/kg/d) (from 1.46 ± 0.21 to 0.74 ±
0.12 a.u.) (Figure 11D). In contrast, NAC treatment had
no significant effect on DHE staining in control spinal
cord (Figure 11B). This is in relation with the increased
protein expression of B1R in the spinal cord of capsai-
cin-treated rats, which was also prevented by pre-treat-
ment with NAC (Figure 12). These data thus suggest
that oxidative stress is invo l v e di nt h ei n d u c t i o no fB 1R
by TRPV1 stimulation. To determine the contribution
of NF-B in this process, expression of p65NF-Bw a s
Figure 8 Tail-flick reaction time of control rats injected with (A) vehicle or capsazepine (10 mg/kg, i.p. or 10 μg/site, i.t.) or (B) vehicle
or SB366791 (1 mg/kg, i.p. or 30 μg/site, i.t.). Tail-flick reaction time was assessed using either a tungsten lamp (A) or a hot water bath (50°
C) as a heat source (B). Data represent the means ± S.E.M. of 4 rats per group.
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cant increase of p65NF-B when compared with control
spinal cords. However, NAC treatment (1 g/kg/d × 7
days) reduced significantly p65NF-Be x p r e s s i o ni nt h e
spinal cord of capsaicin-treated rats. NAC had no effect
in control spinal cord p65NF-B expression (Figure 12).
Changes of IL-1b and TNF-a mRNA levels in the spinal
cord of capsaicin-treated rats
To further determine the mechanism of B1Ri n d u c t i o n
by capsaicin, spinal cord mRNA levels of pro-inflamma-
tory cytokines (IL-1b and TNF-a) known to induce B1R
were assessed using real-time PCR (Figure 13). These
data show a significant increase in IL-1b mRNA expres-
sion (40-fold) in the spinal cord of capsaicin-treated rats
(15 mg/kg, s.c.) when compared with control. This
induction was prevented by the selective TRPV1 antago-
nist capsazepine (10 mg/kg, i.p.) administered 1 h prior
to capsaicin. In contrast, TNF-a mRNA levels were
unaffected by the three doses of capsaicin. Spinal cord
B1Ra n dI L - 1 b mRNA levels following capsaicin chal-
l e n g ew e r eh i g h l yc o r r e l a t e d( R
2= 0.996) while mRNA
levels of B1Ra n dT N F - a (R
2= 0.562) were not
correlated.
Discussion
The present study provides the first pharmacological
evidence that the B1R (mRNA and protein levels) can be
induced and up-regulated in rat spinal cord after sys-
temic or spinal activation of TRPV1 by capsaicin. The
B1R induction mechanism involves oxidative stress, pro-
inflammatory cytokines and the NF-Bp a t h w a y .
Activation of TRPV1 on primary sensory afferents and
microglial cells can enhance superoxide anion produc-
tion [26,28], which is known to induce B1Re x p r e s s i o n
in various tissues [4,8,15]. Hence, the involvement of
oxidative stress in the induction of B1Rb yT R P V 1i s
consistent with these latter studies, as shown with N-
acetyl-L-cysteine treatment that prevented the increased
expression of B1R and superoxide anion levels in the
spinal cord of capsaicin-treated rats. Functionality of the
B1R was demonstrated in thermonociception. The
hyperalgesic response to intrathecally injected B1Ra g o -
nist was ascribed to the intraspinal release of NO and
activation of NK-1R and NMDA-R, as previously
reported following spinal activation of B1R in streptozo-
tocin-diabetic rats [1]. The presence of B1Ri ns p i n a l
cord microglia is consistent with the emerging role of
microglial B1R in pain neuropathy [29,30,49].
TRPV1 activation and inhibition
In this study, TRPV1 was activated with increasing
doses of the lipophilic molecule capsaicin, the active
pungent ingredient of hot chilli peppers [50]. Capsaicin’s
actions are classified into TRPV1-mediated actions
(including some side effects) and TRPV1-independent
effects. TRPV1-mediated side effects include desensitisa-
tion (depletion of SP and CGRP) of C and Aδ neurons
following sub-chronic capsaicin treatment, and neuronal
apoptosis (calcium neurotoxicity) after chronic treat-
ment with high capsaicin doses [50]. As reviewed by the
latter authors, capsaicin TRPV1-independent effects
include: alteration of membrane fluidity [51], inhibition
of platelet aggregation [52], and toxicity to non-TRPV1
Figure 9 Effect of several pharmacological treatments on des-Arg
9-BK- (9.6 nmol/site, i.t.) and SP- (6.6 nmol/site, i.t.) induced thermal
hyperalgesia in capsaicin-treated rats (15 mg/kg, s.c., 24 h earlier). Shown are the maximal hyperalgesic responses measured 1 min post-
injection of the agonist. Rats received intrathecally (10 μg/site, 15 min earlier) either L-NNA, RP-67580, DL-AP5 or vehicle. Control rats were naïve.
Data represent the means ± S.E.M. of 5-7 rats in each group. Comparison to aCSF (*), des-Arg
9-BK in control rats (a) or substance P in control
rats (b) is indicated by *P < 0.05, **P < 0.01, ***
aaa bbb P < 0.001.
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effect of capsaicin on B1R expression is truly mediated
by TRPV1 activation, two classes of TRPV1 antagonists
(capsazepine and SB-366791)w e r eu s e d[ 1 6 ] .A l t h o u g h
high doses of capsazepine can block neuronal voltage-
gated calcium channels [54], it has also been shown that
capsazepine is 10-100 times more potent for TRPV1
than for its off-target [54]. Secondly, we selected SB-
366791 which is known as a more selective and more
potent TRPV1 antagonist than capsazepine [42].
Recently, it has been broadly employed as a selective
TRPV1 antagonist in pain research [55]. In addition to
blocking B1R up-regulation induced by capsaicin, capsa-
zepine and SB-366791 reversed selectively des-Arg
9-BK-
induced hyperalgesia without affecting SP-induced
hyperalgesia. As additional evidence of specificity,
systemic and intrathecal treatments with TRPV1 antago-
nists (capsazepine and SB-366791) had no direct effect
on baseline latency in the tail-flick test. Collectively,
these findings strongly suggest that the induction of B1R
by capsaicin is attributable to TRPV1 stimulation.
Localisation of B1R and site of action for capsaicin
Using a fluorescent B1Rl i g a n d ,B 1Rw a sm o s t l yf o u n d
(87% of positive cells) in microglial cells in the lumbar
spinal cord dorsal horn of capsaicin-treated rats. Such a
cellular localisation on migratory cells can explain the
widespread distribution of B1R binding sites in all spinal
cord laminae. The significant increase of B1Rm R N Ai n
the spinal cord of capsaicin-treated rats also supports a
spinal site rather than a peripheral site (DRG) for B1R
synthesis.
Figure 10 Confocal microscopy pictures of coronal sections of lumbar spinal cord dorsal horn isolated from 15 mg/kg capsaicin-
treated rats. Microglia were labelled with anti-Iba-1 and are shown in panel A. B1R was labelled with N
a-bodipy-des-Arg
9-BK and is shown in
panel B. Co-localization is shown in yellow in panel C. Images are representative of at least 4 sections/rat from 4 rats/group. Scale bar = 8.58
μmeter. No B1R labeling was found in spinal cord of control spinal cord (not shown).
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spinal cord segments innervated by peripheral nocicep-
tors in the stimulated region, suggesting a contribution
of peripheral TRPV1 to the induction of B1Ri nt h e
spinal cord. The enhanced expression of B1Ro nr o s t r a l
segments (T4 and C2) of the spinal cord could be due
to the expression of B1R on migratory microglial cells
after stimulation of sensory fibers by capsaicin.
Our data also suggest that induction of B1R by capsai-
cin is mediated by a central mechanism since TRPV1
antagonists administered intrathecally prevented B1R
mRNA expression and B1R-stimulated thermal hyperal-
gesia. Capsaicin and capsazepine are lipophilic molecules
and SB-366791 is likely to pass the blood-brain barrier
as well [56]. Therefore, systemically administered capsai-
cin is thought to enter the spinal cord to stimulate
TRPV1 located on central sensory terminals, astrocytes
[56] and microglia [56]. Supporting the latter assump-
tion, we showed that 1 μg of capsaicin directly injected
into lumbar spinal cord caused a significant increase in
B1R mRNA, showing that centrally expressed TRPV1
cells can trigger B1R expression.
B1R mRNA expression patterns
Contrarily to B1R mRNA expression, B1R specific bind-
ing sites were shown to be maximally increased by 50
mg/kg capsaicin. This is congruent with the faster
kinetics of B1R mRNA expression after a dose of 50 mg/
k gc a p s a i c i ni nc o m p a r i s o nw i t h1 5m g / k g .A sB 1Ri s
hardly internalised or desensitised [6], its presence on
the cellular membrane can easily outlast the transient
increase of mRNA in response to acute stimulation of
TRPV1. Thus, B1R mRNA changes do not reflect the
expression of B1R on the cellular membrane. The actual
bell-shaped pattern of B1R mRNA expression is not
unique and has been observed in other models of acute
inflammation induced by exposure to increasing concen-
trations of tobacco-smoke condensate [48,57].
Mechanism underlying B1R induction
TRPV1-induced oxidative stress is suggested as the pri-
mary mechanism by which capsaicin induces B1R. This
is supported by the suppression of capsaicin-induced
increase B1R protein expression and NF-kB activation
by the 1-week treatment with the antioxidant N-acetyl-
L-cysteine. This is in line with the findings of Ma et al.
[26], which suggest that TRPV1 activation by capsaicin
increases reactive oxygen species production in mouse
dorsal root ganglion neurons. This can occur through
increased cytosolic calcium influx and activation of
NADPH oxidase [27]. N-acetyl-L-cysteine also prevented
the increased superoxide anion production in the spinal
cord of capsaicin-treated rats. It is noteworthy that N-
acetyl-L-cysteine or a prolonged treatment with another
antioxidant (alpha-lipoic acid) has been shown to pre-
vent rat spinal cord B1R induction in models of diabetes
[8,15] and hypertension [58]. In a model of rat knee
joint-induced arthritis, peripheral TRPV1 and centrally
increased oxidative stress can enhance pro-inflammatory
cytokines production [59], suggesting that these
Figure 11 Confocal microscopy pictures of DHE labelling in spinal cord dorsal horn of 15 mg/kg capsaicin-treated (C, D) and control
(A, B) rats, pre-treated for 7 days with the potent antioxidant N-acetyl-L-cysteine (1 g/kg/day) (B, D) or its vehicle (A, C). Nuclei were
labelled with TO-PRO-3 (blue) and superoxide anion with DHE (red). Scale = 31.75 μm. Data represent the means ± S.E.M. of at least 4 sections/
rat from 4 rats/group. Comparison with control + vehicle (*) or capsaicin + vehicle (+) is indicated by: *
+ P < 0.05.
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of capsaicin on B1R expression. Indeed, stimulation of
TRPV1 causes the release of various pro-inflammatory
cytokines, including interleukin-6 (IL-6) and IL-8 from
human bronchial epithelial cells [60], IL-1ß and trans-
forming growth factor-ß2 from human ORS keratino-
cytes [61], IL-2, IL-4 and interferon-gamma from
cultured murine Peyer’s patch cells [62], or IL-6 release
and NF-B activation in dorsal horn TRPV1-expressing
microglia [63]. Those pro-inflammatory cytokines could
activate NF-B translocation to the nucleus, thereby
increasing B1R expression [1,64,65]. One can suggest
that cytokines may represent key mediators in the
induction of B1R following TRPV1 activation. As indir-
ect evidence, we found that IL-1b mRNA levels are
enhanced and highly correlated with B1R mRNA levels
following TRPV1 stimulation. In contrast, TNF-a is
unlikely to be involved in B1R expression as its mRNA
level was unaffected by capsaicin administration. This is
in agreement with data showing no correlation between
B1R induction and TNF-a expression in tobacco smoke-
induced lung inflammation [48].
B1R activation led to thermal hyperalgesia
TRPV1 activation by capsaicin induced functional B1R
in the rat spinal cord. This is highlighted by the hyperal-
gesia induced by intrathecal administration of B1R selec-
tive agonist (des-Arg
9-BK) in capsaicin-treated rats. This
response was inhibited by SSR240612, a highly selective
and orally active B1R antagonist [38]. In contrast, des-
Arg
9-BK had no effect on the nociceptive threshold in
control rats which is congruent with its weak constitu-
tive expression. The spinal cord activation of tachykinin
NK-1 receptor with SP causes a hyperalgesic response
in the tail-flick test which is associated with glutamate
release and NO production. Indeed, blockade of NOS or
NMDA receptor prevents thermal hyperalgesia induced
by endogenous release of SP following noxious cuta-
neous stimulation or by intrathecal administration of SP
[66-68]. The hyperalgesic response induced by SP has
Figure 12 Control and capsaicin (CAPS, 15 mg/kg, s.c.)-injected rats were pre-treated for 7 days with N-acetyl-L-cysteine (NAC, 1 g/kg/
d) or its vehicle. Protein expression for B1R (37 kDa), p65NF-B (65 kDa) and dynein (70 kDa) was measured on lumbar spinal cord by western
blot. Representative immunoblots are shown in the upper panels while densitometric quantifications of protein expression are shown in lower
panels. Data represent the means ± S.E.M. of 3-4 rats in each group. Comparison with control + vehicle (*) or capsaicin + vehicle (+) is indicated
by ** ++ P < 0.01.
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des-Arg
9-BK. Also, our pharmacological analysis shows
that the hyperalgesic response to B1R agonist is likely
mediated by endogenous release of NO and activation
of NK-1R and NMDA-R. These spinal pro-nociceptive
mediators appear to be tonically active in capsaicin-trea-
ted rats as their inhibition increased the nociceptive
threshold. Hypoalgesia has also been reported with inhi-
bition of NOS with L-NNA in streptozotocin-diabetic
rats [1] or with NMDA receptor blockade [69]. Since
the hyperalgesic response to SP in capsaicin-treated rats
was not significantly altered, the hyperalgesic response
to des-Arg
9-BK is unlikely to be due to an upregulation
of NK-1 receptors or increased SP response in the spinal
cord of capsaicin-treated rats. The TRPV1 antagonists
capsazepine and SB-366791 prevented the hyperalgesia
induced by des-Arg
9-BK but not that evoked by SP, sug-
gesting that this inhibition is highly specific.
Conclusion
This study provides the first evidence that B1R can be
induced and up-regulated in microglia of spinal cord
dorsal horn following activation of TRPV1 by capsaicin.
This up-regulation is correlated with increased expres-
sion of IL-1b and involves ROS generation and the
redox-regulated NF-B pathway. The newly synthesized
B1R is functional as its activation with an agonist caused
thermal hyperalgesia which we attribute to the intrasp-
inal release of NO and activation of NK-1R and
NMDA-R. These findings support the possibility that
microglial B1R contributes to the effect of TRPV1 in
inflammatory pain.
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Figure 13 Changes in IL-1b and TNF-a mRNA levels in lumbar spinal cord of capsaicin-treated rats (0-50 mg/kg, s.c. 24 h earlier). Also
shown is the effect of the TRPV1 antagonist capsazepine (10 mg/kg, i.p.) administered 1 h prior to capsaicin. Data represent the means ± S.E.M.
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